Injectable
Boldix 250
250 mg/mL
Boldix 250 contains boldenone undecylenate, an esterified injectable compound with an extended-release profile. The source associates it with anabolic activity and increased red-blood-cell production, requiring careful professional oversight.
Product Summary
- Product
- Boldix 250
- Strength
- 250 mg/mL
- Dosage Form
- Injectable
Product Information
Professional injectable product profile.
Product overview: Boldix 250 is an oil-based injectable formulation containing boldenone undecylenate at 250 mg per 1 mL. The undecylenate ester gives the formulation an extended-release character compared with shorter ester preparations.
Background and context: The source describes boldenone undecylenate in relation to anabolic activity and increased red-blood-cell production. Those characteristics are relevant to catalogue identification and risk discussion, but they should not be presented as assured outcomes or as support for non-medical use.
Important considerations: Professional review should account for endocrine suppression, androgenic effects, cardiovascular strain, blood-viscosity changes, and broader haematological concerns. The verified carrier system includes pharmaceutical-grade carrier oil, benzyl benzoate, benzyl alcohol, and Miglyol 840, which is recorded as specification data rather than a usage claim.
| Product name | Boldix 250 |
|---|---|
| Strength | 250 mg/mL |
| Active ingredient or blend | Boldenone Undecylenate |
| Composition per 1 mL | Boldenone Undecylenate 250 mg Oil-based injectable solution |
| Dosage form | Oil-based injectable solution |
| Carrier oil | Pharmaceutical-grade carrier oil; benzyl benzoate; benzyl alcohol; Miglyol 840 |
| Pharmaceutical grade | Pharmaceutical grade carrier system stated in the source |
Inquiry
Request product information for Boldix 250.
For product enquiries, portfolio discussion, or category coordination, email info@3xpharma.com.